Dose escalation for non-small cell lung cancer: Analysis and modelling of published literature

Partridge, M.; Ramos, Mónica; Sardaro, Angela; Brada, Michael

doi:10.1016/j.radonc.2011.02.014

Cited by 110 publications

(72 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite radical RT, the 5-year survival rate is 5-14% in patients with locally advanced stage IIIA-B disease (Byhardt et al, 1998;Sause et al, 2000;Socinski et al, 2004). Although survival can be improved by intensifying radiotherapy (Partridge et al, 2011), attempts at dose escalation are limited by radiation damage of normal lung in the form of radiation pneumonitis. The incidence of radiation pneumonitis is dose and volume dependent, and is related to lung volume receiving >20 Gy (V20) with a risk of pneumonitis of over 10% when V20 exceeds 30% (Kwa et al, 1998;Graham et al, 1999;.…”

Section: Introductionmentioning

confidence: 99%

Spect-guidance to Reduce Radioactive Dose to Functioning Lung for Stage III Non-small Cell Lung Cancer

Wang

Wei²,

Ding³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To investigate the treatment effect of additional information obtained by single photon emission computed tomography (SPECT) lung perfusion imaging (LPI) in the radiotherapy planning process for patients with stage III non-small cell lung cancer (NSCLC). Methods: 39 patients with stage III NSCLC were enrolled. Gross tumor volume (GTV) was outlined by SPECT/CT images, SPECT-LPIs being used to define functional lung (FL) and non-functional lung (NFL) regions. Two sets of IMRT plans were designed to deliver 64Gy to PTV. One was a regular IMRT plan using CT images only (Plan 1), and the other was a corresponding IMRT plan using co-registered images (Plan 2

show abstract

Section: Introductionmentioning

confidence: 99%

Spect-guidance to Reduce Radioactive Dose to Functioning Lung for Stage III Non-small Cell Lung Cancer

Wang

Wei²,

Ding³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…A positive association between outcome and dose has previously been reported [11][12][13]. However, unlike other tumour sites [14][15][16][17][18], there is currently a paucity of explicit liver tumour dose-response modelling within the literature [11]. An improved understanding of radiation dose response is necessary to help better inform future dose prescriptions.…”

mentioning

confidence: 99%

Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours

Lausch

Sinclair²,

Lock³

et al. 2013

BJR

View full text Add to dashboard Cite

Objective: The purpose of this study was to seek radiation dose responses separately for primary hepatocellular carcinoma (HCC) and metastatic (MET) colorectal liver tumours to establish tumour control probabilities (TCPs) for radiotherapy (RT) of liver tumours. Methods: The records of 36 HCC and 26 MET colorectal liver tumour patients were reviewed. The median dose per fraction and total dose were 4 Gy (2-10 Gy) and 52 Gy (29-83 Gy) for the HCC group and 3.6 Gy (2.0-13.0 Gy) and 55 Gy (30-80 Gy) for the MET group, respectively. Median tumour diameter was 6.6 cm (3.0-18.0 cm) and 5.0 cm (1.0-13.0 cm) for the HCC and MET groups, respectively. A logistic TCP model was fitted to the response data for each group using the maximum likelihood method.Results: 50% and 90% probabilities of 6-month local control were estimated to be achievable by 2 Gy per fraction equivalent doses (a/b510 Gy) of 53 Gy and 84 Gy for the HCC group and 70 Gy and 95 Gy for the MET group, respectively. Actuarial 1-year local control for the HCC and MET groups was 65% (45-85%) and 32% (6-58%), respectively, whereas median time to failure was 543 days (374-711 days) and 183 days (72-294 days), respectively. Conclusion: Dose-response relationships were found and modelled for the HCC and MET patient groups, with a higher dose required to control MET tumours. RT offers better local control for HCC than for MET colorectal liver tumours at our institution. Advances in knowledge: An improved understanding of radiation dose-response relationships for primary and MET colorectal liver tumours will help inform future dose prescriptions.

show abstract

“…While Intensity Modulated Radiotherapy (IMRT) provides some clinical advantages and allows treatment of patients with large tumours [1], introducing new treatment regimens and techniques can lead to an increase in radiation dose to the lung [2][3][4]. Radiation-induced normal tissue toxicity is a dose-limiting complication, of which radiation pneumonitis (RP) is the most significant [5,6].…”

mentioning

confidence: 99%

Inclusion of functional information from perfusion SPECT improves predictive value of dose–volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: A prospective study

Farr

Kallehauge

Møller

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

Dose escalation for non-small cell lung cancer: Analysis and modelling of published literature

Cited by 110 publications

References 30 publications

Spect-guidance to Reduce Radioactive Dose to Functioning Lung for Stage III Non-small Cell Lung Cancer

Spect-guidance to Reduce Radioactive Dose to Functioning Lung for Stage III Non-small Cell Lung Cancer

Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours

Inclusion of functional information from perfusion SPECT improves predictive value of dose–volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: A prospective study

Contact Info

Product

Resources

About